A Comparison of Fresenius Com.Tec Cell and Spectra Optia Cell Separators for Autologous and Allogeneic Stem Cell Collections: Single Center Experience

Published on Oct 1, 2018in Indian Journal of Hematology and Blood Transfusion 0.47
· DOI :10.1007/s12288-018-0922-4
Serife Medeni Solmaz1
Estimated H-index: 1
Selda Kahraman1
Estimated H-index: 1
(Medical Park)
+ 8 AuthorsFatih Demirkan11
Estimated H-index: 11
(Dokuz Eylül University)
Peripheral blood is the prefered source for hematopoietic stem cells for hematopoietic stem cell transplantation. The efficiency of peripheral blood stem cell (PBSC) collection can vary among devices. In this study we aimed to compare feasibility and effectivity of apheresis procedures of the different systems. Two apheresis systems [Com.Tec (Fresenius Healthcare) and Spectra Optia (Caridian BCT)] were used in our center for the collection of PBSCs for autologous and allogeneic transplantation. We retrospectively analysed 190 apheresis procedures performed in healthy donors and patients between June 2012 and November 2014 in Department of Hematology, Dokuz Eylul University. PBSCS were collected by Fresenius cell separator (64 procedure) or Spectra Optia cell separator (126 procedure). Mobilization treatments were G-CSF (26.8%), cyclophosphamide plus G-CSF (48.4%), prelixafor plus G-CSF (14.7%), ESHAP (10%) and others. Patient and donor characteristics (age, weight, volume processed, disease, mobilization regimes) were similar in Fresenius and Spectra Optia apheresis groups. Altough both collected PBSCs efficiently, the amount of CD34+ cell in product collected by Spectra Optia device was significantly higher (p < 0.05) and product volume was lower than Fresenius Com.Tec significantly (p < 0.05). “CD34+ collection efficiency” with Spectra Optia was significantly higher than Fresenius Com.Tec (CE2: 87%, 70%, p = 0.033) regarding all procedures. High collection efficiency and low product volume may be a significant characteristic of Spectra Optia device (mean 187 mL, product CD34+ cell: 1576 µL).
  • References (19)
  • Citations (0)
Published on Feb 1, 2011in Transfusion 3.42
Suk-Ran Kim4
Estimated H-index: 4
(Samsung Medical Center),
Hae-Kyoung Choung1
Estimated H-index: 1
(Samsung Medical Center)
+ 2 AuthorsEun-Suk Kang13
Estimated H-index: 13
(Samsung Medical Center)
BACKGROUND: This study was conducted to evaluate the performance of the COM.TEC cell separator (Fresenius HemoCare GmbH) for collecting CD34+ cells in pediatric patients who were intended to have autologous peripheral blood progenitor cell transplantation, with respect to collection variables, prediction power of CD34+ cell yield, and influence on donors. STUDY DESIGN AND METHODS: A total of 26 pediatric solid tumor patients who received mobilization chemotherapy and granulocyte–colony-stimulati...
10 Citations Source Cite
Published on Feb 1, 2015in Journal of Clinical Apheresis 2.39
Marleen Neyrinck2
Estimated H-index: 2
(Delta Air Lines),
H. Vrielink15
Estimated H-index: 15
It’s important to work smoothly with your apheresis equipment when you are an apheresis nurse. Attention should be paid to your donor/patient and the product you’re collecting. It gives additional value to your work when you are able to calculate the efficiency of your procedures. You must be capable to obtain an optimal product without putting your donor/patient at risk. Not only the total blood volume (TBV) of the donor/patient plays an important role, but also specific blood values influence ...
12 Citations Source Cite
Published on May 1, 2012in Transfusion 3.42
Susanne Brauninger5
Estimated H-index: 5
Heike Bialleck7
Estimated H-index: 7
+ 3 AuthorsHalvard Bonig27
Estimated H-index: 27
BACKGROUND: Granulocyte–colony-stimulating factor–mobilized peripheral blood stem cells, collected by white blood cell apheresis, are used for more than 80% of allogeneic and most autologous hematopoietic stem cell transplantations. Optimal donor and recipient outcomes require maximized stem cell collection efficiency and minimized non–target cell contamination. Therefore, improved apheresis technology is desirable. The safety and feasibility of apheresis collections with the novel, electronics-...
55 Citations Source Cite
Published on Oct 1, 2005in Bone Marrow Transplantation 4.50
Alois Gratwohl95
Estimated H-index: 95
Helen Baldomero37
Estimated H-index: 37
+ 3 AuthorsAlvaro Urbano-Ispizua46
Estimated H-index: 46
Change in stem cell source for hematopoietic stem cell transplantation (HSCT) in Europe: a report of the EBMT activity survey 2003
94 Citations Source Cite
Published on Jun 1, 2004in International Journal of Hematology 1.94
Sang Kyun Sohn27
Estimated H-index: 27
(Kyungpook National University Hospital),
J. G. Kim28
Estimated H-index: 28
(Kyungpook National University Hospital)
+ 2 AuthorsKyu Bo Lee17
Estimated H-index: 17
(Kyungpook National University Hospital)
The diverse clinical applications of allogeneic peripheral blood stem cells based on use of their advantages are summarized. It is apparent that more stem cells and T-lymphocytes can be harvested by mobilization treatment with cytokines from healthy donors in allogeneic peripheral blood stem cell transplantation (PBSCT) than in bone marrow transplantation. It is also clear that a stronger graft-versus-tumor effect can be induced with allogeneic PBSCT than with bone marrow transplantation. One me...
5 Citations Source Cite
Published on Jul 1, 2012in Biology of Blood and Marrow Transplantation 4.48
Carlos Bachier12
Estimated H-index: 12
Josh Potter1
Estimated H-index: 1
+ 6 AuthorsCharles F. LeMaistre18
Estimated H-index: 18
Seizures as a complication of the infusion of autologous peripheral blood stem cells (PBSC) are rare. Seizures during infusion of autologous PBSC in 3 of our patients prompted us to review our cell therapy and cytapheresis protocols and procedures. We retrospectively analyzed 159 adult patients collected between January 2006 and July 2009. Patients were collected on either the COBE Spectra (Caridian BCT, Lakewood, CO) cell separator (n = 85) or Fresenius AS (Fresenius Kabi AG, Bad Homburg, Germa...
9 Citations Source Cite
Published on May 1, 2003in Transfusion 3.42
Clyde D. Ford5
Estimated H-index: 5
(University of Utah),
K.J. Chan1
Estimated H-index: 1
(University of Utah)
+ 1 AuthorsFinn B. Petersen44
Estimated H-index: 44
(University of Utah)
BACKGROUND : Accurately predicting the outcomes of peripheral blood stem cell harvests is important because unproductive collections are expensive and subject the donor to unnecessary toxicity. STUDY DESIGN AND METHODS : Predictive factors for stem cell mobilization and collection by a retrospective review of 104 consecutive donors were evaluated. RESULTS : Of several previously suggested measures, the peripheral CD34+ cell concentration on the day of harvest (pCD34 DH ) correlated best with tot...
30 Citations Source Cite
Published on Dec 1, 2013in Transfusion and Apheresis Science 1.75
Sabine Flommersfeld2
Estimated H-index: 2
Tamam Bakchoul19
Estimated H-index: 19
(University of Giessen)
+ 3 AuthorsUlrich J. Sachs28
Estimated H-index: 28
(University of Giessen)
Three different apheresis systems were used in our center for the collection of peripheral blood progenitor cells (PBPCs): COM.TEC (Fresenius Healthcare), COBE Spectra, and Spectra Optia (both from Caridian BCT). We compared 131 autologous and 56 allogeneic apheresis procedures to elucidate feasibility and effectiveness of the different systems. Collection efficiacy varied significantly with lowest results obtained with COBE Spectra. COM.TEC and Spectra Optia produced lower WBC contamination tha...
21 Citations Source Cite
Published on Jul 1, 2006in Journal of Clinical Apheresis 2.39
A.L. Basquiera1
Estimated H-index: 1
P. Abichain1
Estimated H-index: 1
+ 4 AuthorsJ.J. García1
Estimated H-index: 1
The number of CD34+ cells in peripheral blood (PB) is a guide to the optimal timing to harvest peripheral blood progenitor cells (PBPC). The objective was to determine the number of CD34+ cells in PB that allows achieving a final apheresis product containing � 1.5 · 10 6 CD34+ cells/kg, performing up to three aphereses. Between March 1999 and August 2003, patients with hematological and solid malignancies who underwent leukapheresis for autologous bone marrow transplantation were prospectively e...
29 Citations Source Cite
Published on Aug 1, 1996in Vox Sanguinis 2.11
Robert Möhle5
Estimated H-index: 5
(Heidelberg University),
Simona Murea9
Estimated H-index: 9
(Heidelberg University)
+ 2 AuthorsR. Haas30
Estimated H-index: 30
(Heidelberg University)
To assess whether measurement of CD34+ cells in the peripheral blood allows one to estimate the progenitor cell yields of subsequent leukapheresis procedures, 733 corresponding blood and leukapheresis samples were analyzed. Peripheral blood progenitor cells of cancer patients were mobilized with hematopoietic growth factors alone or postchemotherapy, and harvested processing 10 liters of blood for each leukapheresis product. The CD34+ cell count (CD34+ cells/μl blood) correlated most closely wit...
44 Citations Source Cite
Cited By0